[Derivatives of 4-phenylpiperidine as substrates of rat brain monoamine oxidase]. 1992

A G Ishkov, and N V Ermakov, and S V Mikerov, and Iu Iu Kliatskiĭ, and E V Miroshnichenko

A rate of utilization of 4-phenyl piperidine and its 12 derivatives by brain monoamine oxidase (MAO) was studied as compared with typical neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The enzyme was isolated from P2 synaptosomal fraction of brain corpus striatum of Sprague-Dawley rats. 10 drugs were oxidized in the MAO-catalyzed reaction with the rate close or similar to the MPTP oxidation while 6 of them exhibited the neurotoxic effect. Analysis of MAO inhibition, using 1 microM of chlorgyline and/or deprenyl, enabled to evaluate the contribution of MAO-A and MAO-B forms to utilization of 1 mM content of the substances studied. MAO-B was shown to oxidize preferably the drugs radicals of which were substituted at 3rd position of the piperidine ring, while MAO-A preferred the derivatives with radical substitution at 4th position. The rate of substrate oxidation was decreased distinctly after introduction of complete substituents into the 3rd and 4th positions of the nitrogenous heterocycle; at the same time, presence of cyclic fluorine-containing structures increased the rate of utilization, similar to that of MPTP oxidation. Derivatives of 4-phenyl piperidine, which contained in a number of drugs, were oxidized in the MAO-catalyzed reactions and might exhibit direct- or side-neurotoxic effects.

UI MeSH Term Description Entries
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D010880 Piperidines A family of hexahydropyridines.
D002384 Catalysis The facilitation of a chemical reaction by material (catalyst) that is not consumed by the reaction. Catalyses
D003010 Clorgyline An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE. Clorgilin,Chlorgyline,Clorgiline
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012642 Selegiline A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl. Deprenalin,Deprenil,Deprenyl,E-250,Eldepryl,Emsam,Humex,Jumex,L-Deprenyl,Selegiline Hydrochloride,Selegiline Hydrochloride, (R)-Isomer,Selegiline Hydrochloride, (R,S)-Isomer,Selegiline Hydrochloride, (S)-Isomer,Selegiline, (R)-Isomer,Selegiline, (R,S)-Isomer,Selegiline, (S)-Isomer,Selegyline,Yumex,Zelapar,E 250,E250
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats

Related Publications

A G Ishkov, and N V Ermakov, and S V Mikerov, and Iu Iu Kliatskiĭ, and E V Miroshnichenko
October 1976, Journal of pharmaceutical sciences,
A G Ishkov, and N V Ermakov, and S V Mikerov, and Iu Iu Kliatskiĭ, and E V Miroshnichenko
August 1962, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
A G Ishkov, and N V Ermakov, and S V Mikerov, and Iu Iu Kliatskiĭ, and E V Miroshnichenko
January 2019, Frontiers in pharmacology,
A G Ishkov, and N V Ermakov, and S V Mikerov, and Iu Iu Kliatskiĭ, and E V Miroshnichenko
August 1986, Biulleten' eksperimental'noi biologii i meditsiny,
A G Ishkov, and N V Ermakov, and S V Mikerov, and Iu Iu Kliatskiĭ, and E V Miroshnichenko
September 1955, Archives of biochemistry and biophysics,
A G Ishkov, and N V Ermakov, and S V Mikerov, and Iu Iu Kliatskiĭ, and E V Miroshnichenko
September 1990, Pigment cell research,
A G Ishkov, and N V Ermakov, and S V Mikerov, and Iu Iu Kliatskiĭ, and E V Miroshnichenko
January 1983, Acta pharmaceutica Suecica,
A G Ishkov, and N V Ermakov, and S V Mikerov, and Iu Iu Kliatskiĭ, and E V Miroshnichenko
April 1994, Journal of medicinal chemistry,
A G Ishkov, and N V Ermakov, and S V Mikerov, and Iu Iu Kliatskiĭ, and E V Miroshnichenko
April 1994, Biochemical pharmacology,
A G Ishkov, and N V Ermakov, and S V Mikerov, and Iu Iu Kliatskiĭ, and E V Miroshnichenko
March 1966, Journal of medicinal chemistry,
Copied contents to your clipboard!